{
  "relevance": {
    "rules": [
      {
        "rule_id": "relevance_rule_1",
        "rule_text": "All abstracts that coincides with disease area of interest (IgAN). This is interpreted as any abstract matching any of the provided client keywords.",
        "processing_type": "keyword_filtering",
        "reasoning": "The rule defines relevance as any abstract related to the disease area of interest, IgAN. All provided client keywords fall under this disease area, so any match to the client keyword list makes an abstract relevant.",
        "include_logic": {
          "any_of": [
            {
              "categories": [
                "Clinical Trial",
                "Company",
                "Disease",
                "Endpoints",
                "Other",
                "Treatment",
                "Treatment Class"
              ],
              "field": "keywords",
              "values": [
                "PROTECT",
                "ALIGN",
                "ORIGIN 3",
                "RUBY-3",
                "NCT05799287",
                "VISONARY",
                "APPLAUSE",
                "Novartis",
                "Roche",
                "Travere Therapeutics",
                "Otsuka",
                "Vera Therapeutics",
                "Alpine Immune Sciences",
                "Vertex Pharmaceuticals",
                "Remegen",
                "IgA Nephropathy",
                "Proteinuria; OR UPCR",
                "UACR",
                "eGFR",
                "KDIGO",
                "Remission",
                "Disease modification",
                "IgA-IgG immune complexes",
                "Subgroup",
                "immunosuppression",
                "non-immunosuppression",
                "pathogenic Mechanisms",
                "B cell depletion +/- B cell activation +/- B cell targeting",
                "MEST-C",
                "treatment options",
                "Clinical Trial Endpoints",
                "Biomarkers",
                "Complement proteins +/- C3 Complement +/- C4 Complement",
                "Standard of care",
                "targeted-release formulation budesonide",
                "Telitacicept",
                "Sparsentan",
                "Iptacopan",
                "Atrasentan",
                "Zigakibart",
                "Povetacicept",
                "Sibeprenlimab",
                "Atacicept",
                "Methylprednisone +/- methylprednisolone",
                "BAFF +/- APRIL; OR APRIL alone; OR BAFF/April; OR Blys/April; OR APRIL/BLyS",
                "AT1/EDNRA antagonist? +/- ERA +/- endothelian receptor antagonist",
                "Complement Factor B inhibitor +/- alternative pathway +/- complement inhibition +/- complement system inhibitors",
                "ENDR Antagonist",
                "Systemic steroid +/- Systemic glucocorticoid +/- Systemic corticosteroid",
                "SGLT2 +/- inhibition",
                "optimized supportive care +/- ACE/ARB +/- RASi +/- RAASi",
                "Gd-IgA OR IgA1 OR Gd-IgA1 OR Galactose deficient",
                "Chinook Therapeutics",
                "Immune Complex",
                "budesonide",
                "prednisone",
                "TRF budesonide",
                "Veloxis",
                "Asahi Kasei",
                "Tarpeyo",
                "Kinpeygo"
              ]
            }
          ]
        },
        "exclude_logic": ""
      }
    ]
  },
  "priorities": {
    "Very High": {
      "rules": [
        {
          "rule_id": "very_high_rule_1",
          "rule_text": "Assigned by the Calliditas team",
          "processing_type": "none",
          "reasoning": "This rule describes a manual assignment process by the client team and cannot be automated based on abstract content.",
          "include_logic": "",
          "exclude_logic": ""
        }
      ]
    },
    "High": {
      "rules": [
        {
          "rule_id": "high_rule_1",
          "rule_text": "All relevant abstracts that include any of the following: Phase 2/3 data (including meta-analyses), real-world data (including patient reported outcomes, retrospective analyses and registry data)",
          "processing_type": "context_filtering",
          "reasoning": "This rule identifies high-impact data types which are not part of the client keyword list and require contextual analysis.",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Data Type"
                ],
                "field": "keywords",
                "values": [
                  "Phase 2",
                  "Phase 3",
                  "Phase II",
                  "Phase III",
                  "meta-analysis",
                  "meta-analyses",
                  "real-world data",
                  "RWD",
                  "real-world evidence",
                  "RWE",
                  "patient reported outcomes",
                  "PRO",
                  "retrospective",
                  "registry"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Internal": {
      "rules": [
        {
          "rule_id": "internal_rule_1",
          "rule_text": "Calliditas sponsored studies",
          "processing_type": "keyword_filtering",
          "reasoning": "This rule identifies studies sponsored by a specific company, 'Calliditas'. This can be treated as a keyword match.",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Company"
                ],
                "field": "keywords",
                "values": [
                  "Calliditas"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Medium": {
      "rules": [
        {
          "rule_id": "medium_rule_1",
          "rule_text": "All relevant abstracts that include any of the following: Phase 1 data, general HEOR studies, prognostic studies, preclinical studies, other general studies",
          "processing_type": "context_filtering",
          "reasoning": "This rule identifies specific study types that are not part of the client keyword list and require contextual analysis. The term 'other general studies' is too broad to be automated.",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Data Type"
                ],
                "field": "keywords",
                "values": [
                  "Phase 1",
                  "Phase I",
                  "HEOR",
                  "health economics",
                  "outcomes research",
                  "prognostic",
                  "preclinical"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Low": {
      "rules": [
        {
          "rule_id": "low_rule_1",
          "rule_text": "All relevant abstracts that only have mention of an indication of interest and does not include any other data",
          "processing_type": "keyword_filtering",
          "reasoning": "This rule acts as a catch-all for relevant abstracts that do not meet higher priority criteria. It is defined by the presence of the core indication keyword. The prioritization engine is expected to handle the 'fall-through' logic where this priority is assigned if no higher priority rule matches.",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Disease"
                ],
                "field": "keywords",
                "values": [
                  "IgA Nephropathy"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Not Relevant": {
      "rules": []
    }
  }
}